Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Yingsheng Biology

Request full access

A pioneer in technology development, quality control, and technical services in the field of clinical mass spectrometry in Chin

Jinan, ChinaBiotech & Life Sciences

About Yingsheng Biology

Shandong Yingsheng Biotechnology Co., Ltd., operating as Yingsheng Biology, is a high-tech enterprise established in 2009 that integrates research and development, production, sales, and third-party medical testing services. The company was founded by Mr. Feng, who currently serves as the Chairman and Managing Director. He and his team are recognized for their deep understanding of the Chinese clinical mass spectrometry market.

Yingsheng Biology focuses on the in vitro diagnostics (IVD) market, particularly in the area of clinical mass spectrometry, which is considered a significant growth area in the diagnostics industry. The firm provides one-stop solutions for clinical mass spectrometry laboratories. Its business model encompasses the entire value chain from manufacturing analytical instruments and automated pre-processing platforms to producing a wide array of IVD reagents and offering medical testing services through its own inspection institutions in Hebei and Shandong. The company generates revenue through the sale of these products and services to hospitals and clinical laboratories.

The company's product portfolio is extensive, built around metabolomics and genomics to address birth defect screening, disease prevention, and human health services. Key products include the YS Ext 9900 and YS Ext 9050MD high-performance liquid chromatography-mass spectrometry (LC-MS) systems and the YS Ext 8600MD inductively coupled plasma mass spectrometer (ICP-MS). Yingsheng Biology also produces a range of diagnostic kits, such as those for neonatal genetic and metabolic disease screening, full-spectrum vitamin testing, and genetic testing for hereditary and drug-induced deafness. In 2020, the company developed a COVID-19 nucleic acid detection kit and received approval for its full-spectrum 14-vitamin testing kit.

Yingsheng Biology has achieved several key milestones, including securing multiple rounds of financing from prominent investors. The company completed a Series B financing round in November 2020 and a Series C round in March 2022, attracting capital from firms like CICC Capital, Far East Horizon, and Hillhouse. These funding rounds have been aimed at accelerating market expansion, consolidating the industrial chain, and maintaining a leading edge in product development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
21
Open positions
None listed
Dealroom signal
23.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology, Medical Devices
Sector
Biotechnology, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES CEquity / VC Mar 2022 — — China Taiping Insurance · Far East Horizon · Sunz Fund · Hillhouse Capital ↗
SERIES B✓Equity / VC Nov 2020 $10M $40M Qianhai FOF · River Head Capital · Hillhouse Capital · CD Capital —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Yingsheng Biology website traffic

Latest recorded traffic for Yingsheng Biology is 1.9K monthly website visits, up 3700% over the last three months. Yingsheng Biology's team grew 0% over the past year.

Latest monthly visits1.9K 3-month web change+3700% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Yingsheng Biology in the Jinan ecosystem

Live from Dealroom

The Yingsheng Biology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Hillhouse Capital
  • Qianhai FOF
  • River Head Capital
  • CD Capital
  • YuanBio Venture Capital
  • GL Ventures

Series B and later5 investors entered at this stage

  • Yuansheng BioVenture
  • Xiamen C&D
  • China Taiping Insurance
  • Far East Horizon
  • Sunz Fund
Employees 21 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Jinan HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Yingsheng Biology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Yingsheng Biology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.